Status:

TERMINATED

A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation

Lead Sponsor:

AbbVie

Conditions:

HIV-1 Infection

Eligibility:

All Genders

18+ years

Brief Summary

This is a mixed prospective-retrospective, multi-center observational study to assess the virologic effectiveness of generic product of Lopinavir/Ritonavir (LPV/r) after switching from Kaletra in the ...

Eligibility Criteria

Inclusion

  • Human Immunodeficiency Virus Type-1 (HIV-1) infected patients on any dual or triple Highly Active Anti-Retroviral Therapy (HAART) with Kaletra under observation at least 48 weeks and with two consequent plasma HIV-1 RNA levels within the last 24 weeks (plasma HIV-1 RNA level \<50 copies/mL) switched to a generic LPV/r as decided by the physician in the routine clinical settings within last 24 weeks from study enrollment date.
  • HIV-1 infected patients with last available CD4+ T-cell count test result \> 200 cells/mm3 before switching from Kaletra.
  • Other (not LPV/r) HAART medicine components of dual or triple HIV therapy not planned to change by regular physician after switching to generic LPV/r.
  • Signed Inform Consent form by patient.

Exclusion

  • Participant has contraindications for the treatment with LPV/r.
  • Legal or physical incapability of patient to sign Inform Consent form

Key Trial Info

Start Date :

November 1 2019

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

July 8 2020

Estimated Enrollment :

239 Patients enrolled

Trial Details

Trial ID

NCT04138199

Start Date

November 1 2019

End Date

July 8 2020

Last Update

July 6 2021

Active Locations (10)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 3 (10 locations)

1

Rep. Cen. of AIDS Profilactis /ID# 216292

Kazan', Tatarstan, Respublika, Russia, 420097

2

Rep Center for the Prev and Control of AIDS and Inf Dis of the MoH of Chuvashia /ID# 216479

Cheboksary, Russia, 428003

3

Reg Ctr for AIDS /ID# 216288

Chelyabinsk, Russia, 454052

4

Reg Ctr for AIDS /ID# 216295

Krasnoyarsk, Russia, 660049

A Study to Assess Effectiveness and Safety of Fixed Dose Combination of Lopinavir/Ritonavir (LPV/r) in Human Immunodeficiency Virus Type 1 (HIV-1) Infected Patients After Switching From Kaletra in the Routine Clinical Settings of Russian Federation | DecenTrialz